agilon health, inc. (AGL)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of agilon health, inc. (“Agilon Health” or “the Company”) (NYSE: AGL). Investors who purchased Agilon Health securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Agilon Health has violated federal securities laws.

Investigation Details:

On January 5, 2024, Agilon Health announced revised guidance expectations for 2023 and stated that “[d]uring 2023, agilon health experienced an increase in medical expenses attributable to higher-than-expected specialist visits, Part B drugs, outpatient surgeries, and supplemental benefits, partially offset by lower hospital medical admissions.” In a separate press release, Agilon Health “announced that Timothy Bensley has informed the company of his intent to retire from his position as Chief Financial Officer (CFO) during 2024, which agilon expects to take place within the next nine months.” On this news, Agilon Health’s stock price fell $3.45 per share, or 28.56%, to close at $8.63 per share on January 5, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Agilon Health securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | [email protected]